千金药业涨2.01%，成交额3572.82万元，主力资金净流入361.13万元

Core Insights - Qianjin Pharmaceutical's stock price increased by 2.01% on November 25, reaching 10.66 CNY per share, with a market capitalization of 5.247 billion CNY [1] - The company reported a revenue of 2.718 billion CNY for the first nine months of 2025, showing a year-on-year growth of 0.14%, and a net profit of 187 million CNY, up 11.47% year-on-year [2] - The company has distributed a total of 2.375 billion CNY in dividends since its A-share listing, with 449 million CNY distributed in the last three years [3] Company Overview - Qianjin Pharmaceutical, established on August 13, 1993, and listed on March 12, 2004, is located in Zhuzhou, Hunan Province [1] - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and women's hygiene products, with revenue contributions of 39.95% from drug wholesale and retail, 28.33% from traditional Chinese medicine production, and 28.28% from Western medicine production [1] Shareholder and Market Activity - As of September 30, 2025, the number of shareholders decreased by 9.85% to 36,800, while the average circulating shares per person increased by 10.92% to 11,360 shares [2] - Major new institutional shareholders include Invesco Great Wall CSI Dividend Low Volatility 100 ETF and Tianhong CSI Dividend Low Volatility 100 ETF, among others [3]